Table 1.
The baseline characteristics of the studied patients (n=73)
| Value | |
|---|---|
| Age (years) | 53.0 (27-79) |
| Gender (male/female) | 54/19 |
| Diagnosis (chronic hepatitis/cirrhosis) | 37/36 |
| AST (IU/L) | 29 (13-425) |
| ALT (IU/L) | 32.0 (8-589) |
| HBV DNA (log10 IU/mL) | 4.11 (1.42-8.23) |
| HBeAg positivity (n, %) | 63 (86.3) |
| Duration of LAM therapy (months) | 32 (15-144) |
| Duration of ETV therapy (months) | 26.5 (20-70) |
| Duration of TDF-based rescue therapy (months) | 37 (6-45) |
| ETV resistant mutations (+M204I/V ± L180M) | |
| 169SMT,184IALT, 202G, 250LV,184LV 202G | 7, 23, 22, 7, 5 |
Continuous variables are expressed as medians with range.
AST, aspartate transaminase; ALT, alanine transaminase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; LAM, lamivudine; ETV, entecavir; TDF, tenofovir disoproxil fumarate.